<DOC>
	<DOC>NCT00038428</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.</brief_summary>
	<brief_title>Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Histologic diagnosis of ovarian cancer Recurrent or persistent disease following primary therapy Measurable disease Prior treatment with at least one but no more than three prior chemotherapy regimens Resistant or refractory to platinumbased chemotherapy At least 18 years of age Good performance status (ECOG 0 to 1) Adequate liver, renal and bone marrow function Exclusion criteria Pregnant or currently breast feeding Treatment with chemotherapy or immunotherapy within four weeks Prior radiation to the whole pelvis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>